HomeCompareBDX vs HII

BDX vs HII: Dividend Comparison 2026

BDX yields 2.27% · HII yields 1.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HII wins by $3.5K in total portfolio value· pulled ahead in Year 6
10 years
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →
HII
HII
● Live price
1.48%
Share price
$369.08
Annual div
$5.46
5Y div CAGR
27.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.4K
Annual income
$2,464.27
Full HII calculator →

Portfolio growth — BDX vs HII

📍 HII pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDXHII
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDX + HII cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDX pays
HII pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
HII
Annual income on $10K today (after 15% tax)
$125.75/yr
After 10yr DRIP, annual income (after tax)
$2,094.63/yr
At 15% tax rate, HII beats the other by $1,195.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDX + HII for your $10,000?

BDX: 50%HII: 50%
100% HII50/50100% BDX
Portfolio after 10yr
$28.7K
Annual income
$1,761.21/yr
Blended yield
6.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDX right now

BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
HII
Analyst Ratings
12
Buy
14
Hold
1
Sell
Consensus: Hold
Price Target
$368.00
-0.3% upside vs current
Range: $264.00 — $421.00
Altman Z
3.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDX buys
12
HII buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$BDX▲ Buy$1,001 - $15,0002025-06-17
Rob Bresnahan🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-15
Thomas H. Kean🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-13
Rob Bresnahan🏢 House$BDX▼ Sell$1,001 - $15,0002025-04-08
Jefferson Shreve🏢 House$BDX▼ Sell$15,001 - $50,0002025-03-05
William R. Keating🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-11
Ro Khanna🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-09
John James🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDXHII
Forward yield2.27%1.48%
Annual dividend / share$3.51$5.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.5%27.9%
Portfolio after 10y$26.9K$30.4K
Annual income after 10y$1,058.14$2,464.27
Total dividends collected$5.7K$9.0K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyHold
Analyst price target$193.80$368.00

Year-by-year: BDX vs HII ($10,000, DRIP)

YearBDX PortfolioBDX Income/yrHII PortfolioHII Income/yrGap
1$10,958$257.59$10,889$189.21+$69.00BDX
2$12,024$299.40$11,898$246.28+$126.00BDX
3$13,214$348.50$13,052$321.65+$162.00BDX
4$14,545$406.26$14,388$421.78+$157.00BDX
5$16,038$474.35$15,951$555.75+$87.00BDX
6← crossover$17,715$554.80$17,804$736.46$89.00HII
7$19,606$650.06$20,032$982.58$426.00HII
8$21,741$763.12$22,756$1,321.55$1.0KHII
9$24,161$897.64$26,144$1,794.47$2.0KHII
10$26,910$1,058.14$30,438$2,464.27$3.5KHII

BDX vs HII: Complete Analysis 2026

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →

HIIIndustrials

Huntington Ingalls Industries, Inc. engages in designing, building, overhauling, and repairing military ships in the United States. It operates through three segments: Ingalls Shipbuilding, Newport News Shipbuilding, and Technical Solutions. The company is involved in the design and construction of non-nuclear ships comprising amphibious assault ships; expeditionary warfare ships; surface combatants; and national security cutters for the U.S. Navy and U.S. Coast Guard. It also provides nuclear-powered ships, such as aircraft carriers and submarines, as well as refueling and overhaul, and inactivation services of ships. In addition, the company offers naval nuclear support services, including fleet services comprising design, construction, maintenance, and disposal activities for in-service the U.S. Navy nuclear ships; and maintenance services on nuclear reactor prototypes. Further, it provides life-cycle sustainment services to the U.S. Navy fleet and other maritime customers; high-end information technology and mission-based solutions for Department of Defense (DoD), intelligence, and federal civilian customers; nuclear management and operations and environmental management services for the Department of Energy, DoD, state and local governments, and private sector companies; defense and federal solutions; and unmanned systems. Huntington Ingalls Industries, Inc. was founded in 1886 and is headquartered in Newport News, Virginia.

Full HII Calculator →
📬

Get this BDX vs HII comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDX vs SCHDBDX vs JEPIBDX vs OBDX vs KOBDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.